Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease

Details

• Alternative Title:
  Drug Alcohol Depend
• Personal Author:
  Cook, Ryan R. ; Torralva, Randy ; King, Caroline ; Lum, Paula J. ; Tookes, Hansel ; Foot, C. anyon ; Vergara-Rodriguez, Pamela ; Rodriguez, Allan ; Fanucchi, Laura ; Lucas, Gregory. M. ; Waddell, Elizabeth N. ; Korthuis, P. Todd
• Description:
  Background.
  
  Associations between fentanyl use and initiation and retention on medications for opioid use disorder (MOUD) are poorly understood.
  
  Methods.
  
  Data were from a multisite clinical trial comparing extended-release naltrexone (XRNTX) with treatment as usual (TAU; buprenorphine or methadone) to achieve HIV viral suppression among people with OUD and uncontrolled HIV disease. The exposure of interest was fentanyl use, as measured by urine drug screening. Outcomes were time to MOUD initiation, defined as date of first injection of XR-NTX, buprenorphine prescription, or methadone administration; MOUD persistence, the total number of injections, prescriptions, or administrations received over 24 weeks; and MOUD retention, having an injection, prescription, or administration during weeks 20 to 24.
  
  Results.
  
  Participants (N = 111) averaged 47 years old and 62% were male. Just over half (57%) were Black and 13% were Hispanic. Sixty-four percent of participants tested positive for fentanyl at baseline. Participants with baseline fentanyl positivity were 11 times less likely to initiate XR-NTX than those negative for fentanyl (aHR = 0.09, 95% CI 0.03 to 0.24, p < .001), but there was no evidence that fentanyl use impacted the likelihood of TAU initiation (aHR = 1.50, 0.67 to 3.36, p = .323). Baseline fentanyl use was not associated with persistence or retention on any MOUD.
  
  Conclusions.
  
  Fentanyl use was a substantial barrier to XR-NTX initiation for the treatment of OUD in persons with uncontrolled HIV infection. There was no evidence that fentanyl use impacted partial/full agonist initiation and, once initiated, retention on any MOUD.
  
  
• Subjects:
  Article Buprenorphine Delayed-Action Preparations Extended-release Naltrexone Fentanyl HIV HIV Infections Humans Male Medications For Opioid Use Disorder Middle Aged Naltrexone Narcotic Antagonists Opioid-Related Disorders Opioid Use Disorder

  More +
• Source:
  Drug Alcohol Depend. 228:109077
• Pubmed ID:
  34600253
• Pubmed Central ID:
  PMC8595584
• Document Type:
  Journal Article
• Funding:
  K24 DA035684/DA/NIDA NIH HHSUnited States/ ; UG1 DA015815/DA/NIDA NIH HHSUnited States/ ; R01 CE003008/CE/NCIPC CDC HHSUnited States/ ; UG1 DA013732/DA/NIDA NIH HHSUnited States/ ; U01 DA047982/DA/NIDA NIH HHSUnited States/ ; UG1 DA013727/DA/NIDA NIH HHSUnited States/ ; K12 HS026370/HS/AHRQ HHSUnited States/
• Volume:
  228
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:87689b94d9eb9ecca4d52668af384fdb8ffc468744e7925da3bbfce15f3f513a
• Download URL:
  https://stacks.cdc.gov/view/cdc/111861/cdc_111861_DS1.pdf
• File Type:
  [PDF - 314.58 KB ]